The glioblastoma findings support our observations regarding the relevance of EndoMT and possible mechanism for resistance to anti-VEGFA in pathologic neovascularization, and suggest further exploration of combination therapy with novel EndoMT inhibitors and anti-VEGFA in neovascular disorders. This evidence concerns the gene VEGFA and glioblastoma.